News

Mexico City - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Vida y Familia México, I.A.P. ("VIFAC") to support programs that promote maternal and child health and address health disparities.

Apotex Inc. today announced a grant through the Apotex Global Health Access Fund to Healthy Mothers, Healthy Babies Coalition of Broward County (“HMHB/Broward”) in Lauderhill, Florida, to support programs that promote maternal health and address health disparities.

Apotex Inc., the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the United States rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil).

Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.

Oxcarbazepine ER tablets are an oral once-a-day anticonvulsant indicated for the treatment of partial-onset seizures in patients 6 years of age and older.

Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Harrow, Inc., a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.